肿瘤浸润淋巴细胞在乳腺癌诊治中的争议与共识  

Controversy and consensus on the role of tumor infiltrating lymphocytes in the diagnosis and treatment of breast cancer

作　　者：张文静 周毅[1] 冀亮[1] Wenjing Zhang;Yi Zhou;Liang Ji(Department of Breast Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin 150007,China)

机构地区：[1]哈尔滨医科大学附属第一医院乳腺外科,哈尔滨市150007

出　　处：《中国肿瘤临床》2025年第5期244-247,共4页Chinese Journal of Clinical Oncology

基　　金：课题受国家自然科学基金面上项目(编号:82270668)资助。

摘　　要：近年来,乳腺癌的发病率逐步上升,如何更加有效、精准地诊断和治疗一直是研究的热点问题。肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)是乳腺癌重要的生物学标志物,然而,其临床指导价值尚未得到广泛认同。TILs的临床应用仍然存在一系列瓶颈,如何实现评估标准化、TILs阈值的设定以及能否用无创检测的方法评估TILs等,这是TILs在实际临床工作中存在争议的重要原因。TILs对于乳腺癌的预后评估、疗效预测等方面的价值不容忽视,有利于推动乳腺癌的精准化、个体化治疗。本文将综合分析目前TILs在乳腺癌诊治过程中的争议与共识,以期为TILs的合理应用提供依据。The incidence of breast cancer(BC)is on the rise.The effective and precise management of BC continues to be topical.Tumor in-filtrating lymphocytes(TILs),significant biomarkers indicative of the biological behavior of BC,have not been well recognized in clinical prac-tice.There are some impediments,including the lack of a standard protocol for the quantification of TILs,an optimized threshold for TILs,and a repeatable noninvasive method for the assessment of TILs.These issues are the major controversies preventing the use of TILs as bio-markers in the clinical management of BC.Nevertheless,the value of TILs as biomarkers in the assessment of the prognosis and prediction of the response to treatment cannot be neglected,as they show promise in promoting precise and individualized management of BC.We aimed to offer a comprehensive outline of the current controversies and consensus regarding TILs as biomarkers in the management of BC,with the aim of providing a basis for the rational application of TILs as biomarkers.

关 键 词：肿瘤浸润淋巴细胞 乳腺癌 分子分型 精准治疗 

分 类 号：R737.9[医药卫生—肿瘤]